ReviewJournal of internal medicine2014
Recent advances towards tuberculosis control: vaccines and biomarkers.
Review in Journal of internal medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 92 citations in OpenAlex.
- Alterations in the Immune Response in Individuals with Latent Tuberculosis Infection.Pathogens (Basel, Switzerland) · 2025Review
- Lipid Antigens: Revealing the Hidden Players in Adaptive Immune Responses.Biomolecules · 2025Review
- Review
- Identification of host biomarkers from dried blood spots for monitoring treatment response in extrapulmonary tuberculosis.Scientific reports · 2023Article
- Controlled Human Infection Models To Accelerate Vaccine Development.Clinical microbiology reviews · 2022Review
- Recent developments in systems biology and genetic engineering toward design of vaccines for TB.Critical reviews in biotechnology · 2022Review
- Exploring the value of Mycobacterium tuberculosis modified lipoprotein as a potential biomarker for TB detection in children.BMC infectious diseases · 2022Article
- Tuberculosis: The success tale of less explored dormantFrontiers in cellular and infection microbiology · 2022Review
- Increased UBE2L6 regulated by type 1 interferon as potential marker in TB.Journal of cellular and molecular medicine · 2021Article
- Monocyte progenitors give rise to multinucleated giant cells.Nature communications · 2021Article
- Recombinant BCG expressing the LTAK63 adjuvant induces increased early and long-term immune responses against Mycobacteria.Human vaccines & immunotherapeutics · 2020Article
- Vaccination Against Tuberculosis: Revamping BCG by Molecular Genetics Guided by Immunology.Frontiers in immunology · 2020Review
- Cell-Mediated Immune Responses toFrontiers in immunology · 2020Article
- IP-10 dried blood spots assay monitoring treatment efficacy in extrapulmonary tuberculosis in a low-resource setting.Scientific reports · 2019Article
- BCG Vaccination Prevents Reactivation of Latent Lymphatic Murine Tuberculosis Independently of CD4Frontiers in immunology · 2019Article
- Comparative Study of the Molecular Basis of Pathogenicity ofInternational journal of molecular sciences · 2018Article
- Lessons from the first clinical trial of a non-licensed vaccine among Ugandan adolescents: a phase II field trial of the tuberculosis candidate vaccine, MVA85A.Wellcome open research · 2018Article
- Mycobacteria exploit nitric oxide-induced transformation of macrophages into permissive giant cells.EMBO reports · 2017Article
- A temperature sensitive Mycobacterium paragordonae induces enhanced protective immune responses against mycobacterial infections in the mouse model.Scientific reports · 2017Article
- A mycobacterial growth inhibition assay (MGIA) for bovine TB vaccine development.Tuberculosis (Edinburgh, Scotland) · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Of all infectious diseases, tuberculosis (TB) remains one of the most important causes of morbidity and mortality. Recent advances in understanding the biology of Mycobacterium tuberculosis (Mtb) infection and the immune response of the infected host have led to the development of several new vaccines, a number of which are already undergoing clinical trials. These include pre-exposure prime vaccines, which could replace bacille Calmette-Guérin (BCG), and pre-exposure booster vaccines given in addition to BCG. Infants are the target population of these two types of vaccines. In addition, several postexposure vaccines given during adolescence or adult life, in addition to BCG as a priming vaccine during infancy, are undergoing clinical testing. Therapeutic vaccines are currently being assessed for their potential to cure active TB as an adjunct to chemotherapy. BCG replacement vaccines are viable recombinant BCG or double-deletion mutants of Mtb. All booster vaccines are composed of one or several antigens, either expressed by viral vectors or formulated with adjuvants. Therapeutic vaccines are killed mycobacterial preparations. Finally, multivariate biomarkers and biosignatures are being generated from high-throughput data with the aim of providing better diagnostic tools to specifically determine TB progression. Here, we provide a technical overview of these recent developments as well of the relevant computational approaches and highlight the obstacles that still need to be overcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.